他汀类药物在冠状动脉介入术前应用分析

Application of statins before percutaneous coronary intervention

目的分析冠状动脉介入(PCI)治疗前患者服用他汀类药物对预后状况的影响。方法选择116例行PCI治疗的病患,随机分组,I组62例与II组54例患者行相同治疗,I组治疗前另行服用他汀类药物阿托伐他汀,治疗24周之后,观察两组患者出现MACCE(心脑血管事件)的情况及血液流变指数、血脂生化指标的变化状况,总结他汀类药物用于患者PCI治疗的价值。结果以他汀类药物配合PCI治疗的I组患者MACCE总发生率为4.84%(3/62),明显比II组(24.07%)低,P<0.05;且I组术后的血液流变指标基本维持在正常范围,II组均高于正常水平,I组明显低于II组;两组患者血脂生化指标均有所降低,I组TC、TG、HDL-C降低比II组显著,P<0.05,LDL-C与II组相比则降低不明显,P<0.05。结论医师使用他汀类药物为行PCI的患者进行辅助治疗,可以有效降低MACCE发生率,控制血液流变及血脂生化指标,改善患者预后效果。

Objective To analyze the effect of statins administered before percutaneous coronary intervention （PCI） on patients＇ prognosis. Methods One hundred and sixteen patients treated with PCI were randomly divided into group I （n=62） and group II （n=54）, who received the same PCI operation, but the patients in group I were administered atorvastatin before operation. Twenty-four weeks after PCI, the incidence of major adverse cardiac and cerebral events （MACCE）, hemorheological indices, and blood lipids including total cholesterol （TC）, triglyceride （TG）, high-density lipoprotein-cholesterol （HDL-C）, and low-density lipoprotein-cholesterol （LDL-C） were compared between the two groups The value of statins in PCI treatment was summarized. Results Group Ⅰ had significantly lower incidence of MACCE than group Ⅱ （4.84% vs 24.07%, P〈0.05）. The hemorheological indices of group Ⅰ （within the normal range） were significantly lower than those of group Ⅱ（higher than the normal range）. The blood lipid levels were decreased in both groups; group Ⅰ had significantly higher decreases in TC, TG, and HDL-C than group Ⅱ （P〈0.05）, while there was no significant difference in decrease in LDL-C between group Ⅰ and group Ⅱ （P〈0.05）. Conclusion The application of statins in PCI treatment as an adjuvant therapy can effectively reduce the incidence of MACCE, control the hemorheological indices and blood lipids, and improve patients prognosis.